Legend Biotech (NASDAQ:LEGN) CEO Ingrid Zhang Buys 20,000 Shares of Company Stock

Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN – Get Free Report) CEO Ingrid Zhang acquired 20,000 shares of the stock in a transaction dated Tuesday, November 17th. The shares were bought at an average cost of $8.16 per share, with a total value of $163,200.00. Following the completion of the purchase, the chief executive officer directly owned 1,151,860 shares in the company, valued at approximately $9,399,177.60. This trade represents a 1.77% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Legend Biotech Stock Performance

LEGN stock opened at $15.25 on Friday. The business has a fifty day simple moving average of $19.17 and a 200-day simple moving average of $22.09. Legend Biotech Corporation Sponsored ADR has a 52 week low of $15.15 and a 52 week high of $37.50.

Legend Biotech (NASDAQ:LEGN – Get Free Report) last issued its earnings results on Tuesday, November 10th. The company reported $0.14 earnings per share for the quarter, beating analysts’ consensus estimates of $0.01 by $0.13. Legend Biotech had a negative return on equity of 0.03% and a negative net margin of 0.02%. The firm had revenue of $359.50 million for the quarter, compared to analysts’ expectations of $361.46 million. During the same quarter last year, the firm earned ($0.05) earnings per share. The firm’s revenue for the quarter was up 32.0% compared to the same quarter last year. Research analysts expect that Legend Biotech Corporation Sponsored ADR will post 0.13 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the company. JPMorgan Chase & Co. decreased their target price on Legend Biotech from $35.00 to $33.00 and set a “neutral” rating for the company in a report on Friday, October 9th. Weiss Ratings raised shares of Legend Biotech from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, November 9th. Wall Street Zen upgraded shares of Legend Biotech from a “hold” rating to a “buy” rating in a research note on Saturday, November 14th. Evercore downgraded shares of Legend Biotech from an “outperform” rating to an “in-line” rating and set a $20.00 price objective for the company. in a research note on Friday, November 13th. Finally, HC Wainwright reissued a “buy” rating on shares of Legend Biotech in a research report on Friday, October 30th. Nine analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $48.64.

Get Our Latest Research Report on LEGN

Institutional Investors Weigh In On Legend Biotech

Several institutional investors and hedge funds have recently modified their holdings of the stock. Parallel Advisors LLC raised its holdings in shares of Legend Biotech by 173.9% during the 1st quarter. Parallel Advisors LLC now owns 2,084 shares of the company’s stock valued at $38,000 after buying an additional 1,323 shares during the period. Toth Financial Advisory Corp purchased a new position in Legend Biotech in the 3rd quarter worth approximately $50,000. Public Employees Retirement System of Ohio acquired a new stake in Legend Biotech in the second quarter valued at approximately $92,000. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Legend Biotech in the third quarter valued at approximately $136,000. Finally, Nykredit A S acquired a new stake in Legend Biotech in the second quarter valued at approximately $162,000. Hedge funds and other institutional investors own 70.89% of the company’s stock.

Latest Legend Biotech News

These are some of the LEGN news items that stood out recently:

  • Positive Sentiment: HC Wainwright maintained its Buy rating and forecasts Legend Biotech will earn $0.24 per share in FY2026, followed by $1.18 per share in FY2027. A separate report cites a brokerage consensus price target of $50.85. Brokerage consensus price target report
  • Neutral Sentiment: A recent article asks whether a return to profitability changes the investment case, but the available report details do not specify its conclusions. Yahoo Finance article on Legend Biotech’s return to profit
  • Negative Sentiment: HC Wainwright cut its EPS estimates across several upcoming periods: FY2027 to $1.18 from $1.70, Q1 2027 to $0.14 from $0.26, and Q2 2027 to $0.22 from $0.36. It also reduced its Q3 and Q4 2027 forecasts. The broad revisions signal a less favorable earnings outlook and could pressure the shares, although the firm kept its Buy rating. Legend Biotech stock and analyst information

About Legend Biotech

(Get Free Report)

Legend Biotech is a biotechnology company focused on developing cell therapies for cancer, with an emphasis on chimeric antigen receptor (CAR) T-cell treatments. Founded in 2014, the company is headquartered in Somerset, New Jersey, and conducts research and development activities in the United States and China. Its lead product is CARVYKTI (ciltacabtagene autoleucel), a BCMA-directed CAR-T therapy for certain adults with relapsed or refractory multiple myeloma. Legend developed the therapy with Janssen, now part of Johnson & Johnson’s Innovative Medicine business, which collaborates on its commercialization.

Recommended Stories

Receive News & Ratings for Legend Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Legend Biotech and related companies with MarketBeat.com's FREE daily email newsletter.